Page 1 of 8
`
`Helsinn Healthcare Exhibit 2063
`Dr. Reddy's Laboratories, Ltd., et al. v. Helsinn Healthcare S.A.
`Trial PGR2016-00007
`
`

`
`
`
`eceipt daie: 12/20/2011
`
`
`
`
`
`INFORMATION DISCLOSURE
`
`
`
`S“‘TE“"E””’”""”°““T
`
`
`
`
`
`
`
`(Not for submission under 37 CFR 1.99)
`
`
`
`
`
`
`Filing Date
`
`
`
`
`
`
`13087012
`2011-04-14
`
`
`
`First Named Inventor
`
`
`
`
`
`
`Giorgio Calderari
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`13087012 ~ QAU: 1628
`
`
`
`1991-07-23
`
`
`
`
`
`1993-08-31
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`5034398
`
`5240954
`
`5344658
`
`
`
`
`
`
`
`1994-09-06
`
`
`
`
`
`
`
`
`
`
`
`
`
`5578628
`
`1996-11-26
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`5578632
`
`5622720
`
`5922749
`
`5955488
`
`6063802
`
`6294548
`
`5854270
`
`1996-11-26
`
`1997-04-22
`
`1997-07-13
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1999-09-21
`
`
`
`Winterborn
`
`
`2000-05-16
`
`2001-09-25
`
`1998-12-29
`
`
`
`
`
`
`
`Winterborn
`
`
`
`
`Gambhir, Renu
`
`
`
`EFSWeb2.1.17
`
`
`
`
`
`
`
`
`
`
`
`ALL REFERENCES CONSHDERED EXCEPT WHERE UNEE) THROUGH.
`
`
`
`/SG./’
`
`
`
`Page 2 of 8
`
`

`
`
`
`ecelpt date: 12/20/2011
`
`
`
`
`
`INFORMATION DISCLOSURE
`
`
`
`S“‘TE“"E””’”""”°““T
`
`
`
`
`
`
`
`(Not for submission under 37 CFR 1.99)
`
`
`
`
`
`
`Filing Date
`
`
`First Named Inventor
`
`
`
`
`
`
`
`13087012
`2011-04-14
`
`
`
`
`Giorgio Calderari
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`13087012 ~ QAU: 1628
`
`
`
`
`
`
`
`
`
`5202333
`
`
`
`1993-04-13
`
`
`
`Berger et al.
`
`
`
`
`6287592
`
`
`
`2001-09-11
`
`
`
`Dickinson, Jeffrey
`
`
`
`
`6284749
`
`
`
`2001-09-04
`
`
`
`
`
`
`
`
`
`If you wish to add additional U.S. Patent citation information please click the Add button.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`U.S.PATENT APPLICATION PUBLICATIONS
`
`
`
`
`
`
`
`
`
`Publication
`
`
`Cite NO Number
`
`
`
`
`
`
`Kind
`
`
`
`
`
`
`
`
`
`
`Publication
`
`
`Name of Patentee or Applicant
`
`
`
`
`of cited Document
`
`
`
`
`Pages,Co|umns,Lines where
`
`
`Relevant Passages or Relevant
`
`
`
`Figures Appear
`
`
`
`
`
`
`
`20010020029
`
`20030095926
`
`
`
`
`
`2001-09-06
`
`2003-05-22
`
`
`
`
`
`
`
`Dugger, |||
`
`
`
`
`If you wish to add additional U.S. Published Application citation information please click the Add button.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`FOREIGN PATENT DOCUMENTS
`
`
`
`
`
`
`
`.
`.
`.
`Examiner Cite Foreign Document
`
`
`
`Number3
`
`
`
`
`
`
`
`
`
`
`.
`
`
`
`.
`.
`Publication
`Date
`
`
`
`
`
`
`Name of Patentee or
`
`
`
`
`
`
`Applicant of Cited
`Document
`
`
`
`
`
`
`
`
`2
`
`2004067005
`
`
`
`03/100091
`
`
`
`
`
`
`
`2004-08-12
`
`
`
`Helsinn Healthcare S.A.
`
`
`
`
`2003-12-04
`
`
`
`Brockmbller
`
`
`
`
`
`
`
`PageS’CO|UmnS’LineS
`where Relevant
`
`
`Passages or Relevant
`
`
`.
`Figures Appear
`
`
`
`
`
`
`
`
`
`
`
`EFSWeb2.1.17
`
`
`
`
`
`
`
`
`
`
`ALL REFERENCES CONSHDEREED EXCEPT WHERE UNEE) THROUGH.
`
`
`
`/SG./’
`
`
`
`Page 3 of 8
`
`

`
`
`
`ecelpt date: 12/20/2011
`
`
`
`
`
`INFORMATION DISCLOSURE
`
`
`
`S“‘TE“"E””’”""”°““T
`
`
`
`
`
`
`
`(Not for submission under 37 CFR 1.99)
`
`
`
`
`
`
`Filing Date
`
`
`
`
`
`
`13087012
`2011-04-14
`
`
`
`First Named Inventor
`
`
`
`
`
`
`Giorgio Calderari
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`13087012 ~ GAU: 1628
`
`
`
`
`
`
`
`2004703714
`
`2004045615
`
`
`
`
`
`
`
`
`
`2004-09-02
`
`2004-06-03
`
`
`
`
`
`Helsinn Healthcare S.A.
`
`
`
`
`
`Helsinn Healthcare S.A.
`
`
`
`
`
`If you wish to add additional Foreign Patent Document citation information please click the Add button
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`NON-PATENT LITERATURE DOCUMENTS
`
`
`
`
`
`
`
`Examiner Cite
`
`
`
`
`
`
`
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`
`
`
`
`
`
`
`
`
`
`
`publisher, city and/or country where published.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Opposition Brief filed by Dr. Reddy's Laboratories (UK) Limited, opposition to European Patent No. 1601359 B1, July
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`7,2009
`
`
`
`
`Photolytic and oxidative degradation of an antiemetic agent, RG 12915 (Won C. M. Et al, International Journal of
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pharmaceutics 121 (1995) 95-105 (1995)
`
`
`
`
`
`
`
`
`Palonosetron: a phase II dose ranging study to assess over a 7 day period the single dose pharmacokinetic profile of
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`palonosetron in patients receiving highly emetogenic chemotherapy. Piraccini Get al., Proc. Am. Soc. Clin. Oncol
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2002 21 Abs 449 (2002)
`
`
`
`
`
`
`
`
`Formulation and administration techniques to minimize injection pain and tissue damage associated with parenteral
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`products. Larry A. Gatlin; Carol A Brister Gatlin, [from Injectable Drug Development: Techniques to Reduce Pain and
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Irritation" [Edited by Pramod K. Gupta, Gayle A. Brazeau; Published by lnforma Health Care (original copyright of 1999
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`by lnterpharma Press), 1999; ISBN 1574910957, 9781574910957)], p. 401-421
`
`
`
`
`
`
`
`
`
`
`
`
`Parenteral Dosage Forms. Joanne Broadhead. [from Part 11- Early drug development, Pharmaceutical preformulation
`
`
`
`
`
`
`
`
`
`
`
`and formulation: a practice guide from candidate drug selection to commercial dosage form" [Edited by Mark Gibson;
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Published by lnterpharma Press, 2001; ISBN 1574911201, 9781574911206)], p. 331-353
`
`
`
`
`
`
`
`
`
`
`
`
`
`Opposition Brief filed by Tecnimede Sociedade Tecnico-Medicinal S.A., opposition to European Patent No. 1601359
`
`
`
`
`
`
`
`
`
`
`
`
`
`B1, July 8, 2009
`
`
`
`
`
`
`
`Response brief filed by Helsinn Healthcare S.A. dated July 13, 2007, in response to the communication pursuant to
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Art. 96(2) EPC of 3 January 2007 regarding Serial Number 04 706 6576-2123
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`EFSWeb2.1.17
`
`
`
`
`
`
`
`
`
`
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`
`
`/SG./’
`
`
`
`Page 4 of 8
`
`

`
`
`
`swim dew 12/20/201 1
`
`
`
`
`
`INFORMATION DISCLOSURE
`
`
`
`S“‘TE“"E””’”""”°““T
`
`
`
`
`
`
`
`
`(Not for submission under 37 CFR 1.99)
`
`
`
`
`
`
`
`Filing Date
`
`
`First Named Inventor
`
`
`
`
`
`2011-04-14
`
`Giorgio Calderari
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`_\ C)
`
`
`
`European Patent Office official communication dated July 19, 2006 regarding Serial No. 04 706 657.6
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Response of Helsinn Healthcare S.A. dated November 29, 2006 regarding EPO official communication dated July 19,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2006
`
`
`
`
`Lachman et al., The Theory and Practice of Industrial Pharmacy, 1986, third edition, pp. 652-784
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Summary of Product Characteristics for Aloxi 250 (2009)
`
`
`
`
`
`
`
`
`
`
`_\
`
`1
`
`
`
`
`
`Declaration of Valentino J. Stella, Ph.D. dated September 19, 2007
`
`
`
`
`
`
`
`
`
`
`
`
`Opposition Brief filed by Martin Paul White, opposition to European Patent No. 1601359 B1, July 8, 2009
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`_\ -l>
`
`
`
`Wong et al. (1995), in British Journal of Pharmacology, volume 114, pages 851-859 and Eglen et al. (1995), in British
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Journal of Pharmacology, volume 114, pages 860-866
`
`
`
`
`
`
`
`
`
`
`Cover page and pages 642-644 and 783-784 of The Theory and Practice of Industrial Pharmacy, Third Edition, Lea
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`and Febiger (1986)
`
`
`
`
`
`
`Cover page and pages 514-515 of Modern Pharmaceutics, Second Edition, Marcel Dekker (1990)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Cover page and pages 142-143 of Pharmaceutical Dosage Forms: Parenteral Medications Volume 1, Second Edition,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Marcel Dekker (1992)
`
`
`
`
`
`
`Scientific Discussion from the European Public Assessment Report for Aloxi (Palonosetron Hydrochloride) (2006)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`EFSWeb2.1.17
`
`
`
`
`
`
`
`
`
`
`
`ALL REFERENCES CONSKDEREED EXCEPT WHERE UNEE) THROUGH.
`
`
`
`/SG./’
`
`
`
`Page 5 of 8
`
`

`
`
`
`so-elpt date: 12/20/2011
`
`
`
`
`
`INFORMATION DISCLOSURE
`
`
`
`S“‘TE“"E””’”""”°““T
`
`
`
`
`
`
`
`(Not for submission under 37 CFR 1.99)
`
`
`
`
`
`
`Filing Date
`
`
`
`
`
`
`13087012
`2011-04-14
`
`
`
`First Named Inventor
`
`
`
`
`
`
`Giorgio Calderari
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`13087012 ~ QAU: 1628
`
`
`
`
`
`
`
`
`
`l\JI\)[0l\)l\)01-l>(.0l\)A
`
`
`
`
`
`
`
`
`
`Mitsuo Matsumoto, et al., "Yakuzaigaku Manual", 1st edition, Nanzando Co., Ltd. (1989) 2 pages
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Michael J. Pikal, "Freeze Drying", Encyclopedia of Pharmaceutical Technology, Third Edition, January 2007, Pages
`
`
`
`
`
`
`
`
`
`
`
`
`
`1824-1825, Volume 3, lnforma Pharmaceuticals & Healthcare
`
`
`
`
`
`
`
`
`
`
`Daniele Bonadeo, "Supplemental Declaration of Daniele Bonadeo 37 C.F.R. 1.132", U.S. Patent Application Serial No.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`11/388,270, June 8, 2009
`
`
`
`
`
`Kranke et al. 2007, "Recent advances, trends and economic considerations in
`
`
`
`
`
`
`
`
`
`
`
`(18): 3217-3235)
`
`
`
`"Expert Opinion Pharmacother., 8
`
`
`
`
`
`
`
`
`Morrow et al. 1995, Progress in reducing nausea and emesis. Comparisons of ondansetron, granisetron, and
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`tropisetron. Cancer, Volume 76 No. 3 pages 343-357
`
`
`
`
`
`
`
`
`
`USPTO Notice of Allowance and Fee Due, USSN 11/388,270, Filing Date 03/24/2006, Date Mailed 01/26/2010
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`USPTO Office Action, USSN 11/129,839, Date Mailed 01/15/2010
`
`
`
`
`
`
`
`
`
`
`I\)G
`
`
`
`lsraili, Zafar H., Clinical Pharmacology of Serotonin Receptor Type—3 (5—HT3) Antagonists, Curr. Med. Chern.— Central
`
`
`
`
`
`
`
`
`
`
`
`
`
`Nervous System Agents, 2001, 1, 171-199
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Barton (Citrate Buffer Calculation), 2000, 2 pages
`
`
`
`
`
`
`
`
`
`USPTO Office Action, USSN 11/201,035, Date Mailed 08/19/2009
`
`
`
`
`
`
`
`
`
`
`Response of Helsinn Healthcare to opposition of EP Serial No. 04 706 657.6 dated February 11, 2010
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`EFSWeb2.1.17
`
`
`
`
`
`
`
`
`
`
`
`ALL REFERENCES CONSll3EREl3 EXCEPT WHERE l_ll\lEE) THROUGH.
`
`
`
`/SG./’
`
`
`
`Page 6 of 8
`
`

`
`
`
`swim date 12/20/201 1
`
`
`
`
`
`INFORMATION DISCLOSURE
`
`
`
`S“‘TE“"E””’”""”°““T
`
`
`
`
`
`
`
`
`(Not for submission under 37 CFR 1.99)
`
`
`
`
`
`
`
`Filing Date
`
`
`First Named Inventor
`
`
`
`
`
`2011-04-14
`
`Giorgio Calderari
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Annex 1 (Statement of Waldo Mossi, Ph.D.) to Response of Helsinn Healthcare to opposition of EP Serial No. 04 706
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`657.6 dated February 11,2010
`
`
`
`
`
`
`
`0) _\
`
`
`
`
`
`
`
`
`
`
`
`
`U)(A)U)U)(,0
`
`Annex 2 to Response of Helsinn Healthcare to opposition of EP Serial No. 04 706 657.6 dated February 11, 2010
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Annex 3 to Response of Helsinn Healthcare to opposition of EP Serial No. 04 706 657.6 dated February 11, 2010
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`6th Edition, Handbook of Pharmaceutical Excipients (2009), pp. 247-250n (RPS Publishing)
`
`
`
`
`
`
`
`
`
`
`
`
`
`USPTO Office Action, USSN 11/388,268, Filing Date 03/24/2006, Mail Date 03/29/2010
`
`
`
`
`
`
`
`
`
`
`
`
`
`Lewis, Gareth A (2006), ‘Optimization Methods,‘ Encyclopedia of Pharmaceutical Technology, 1: 1, 2452-2467
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Chelly, Jacques et al., Oral RS-25259 Prevents Postoperative Nausea and Vomiting Following Laparoscopic
`
`
`
`
`
`
`
`
`
`
`
`
`Surgery, extracted from Anesthesiology, 1996, vol. 85 no. 3A. p. A21.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`(A) \l
`
`
`Sorbe, Bengt, 5—HT3 Receptor Antagonists as Antiemetic Agents in Cancer Chemotherapy, extracted from
`
`
`
`
`
`
`
`
`
`
`
`
`
`Expert Opinion on lnvestigational Drugs, 1996, vol. 5 no. 4, pp. 389-407.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Gaster, Laramie M. and King, Frank D., Serotonin 5—HT3 and 5-HT4 Receptor Antagonists, extracted from
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Medicinal Research Reviews, 1997 vol. 17, no. 2, pp. 163-214.
`
`
`
`
`
`
`
`
`
`
`
`
`
`Tang, Jun et al., Efficacy of RS-25259, a Novel 5—HT3 Antagonist, in the Prevention of Postoperative Nausea
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`and Vomiting After Major Gynecologic Surgery, abstract extracted from Anesthesiology, 1997, vol. 85, no. 3,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`suppl. p. A329.
`
`
`
`
`
`
`Tang, Jun et al., The Efficacy of RS-25259, a Long-Acting Selective 5—HT3 Receptor Antagonist, for Preventing
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Postoperative Nausea and Vomiting After Hysterectomy Procedures, extracted from Anesthesia and Analgesia,
`
`
`
`
`
`
`
`
`
`
`
`
`1998, vol. 87, pp. 462-7.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`EFSWeb2.1.17
`
`
`
`
`
`
`
`
`
`
`
`ALL REFERENCES CONSHDERED EXCEPT WHERE UNEE) THROUGH.
`
`
`
`
`
`Page 7 of 8
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Mimi date 12/20/201 1
`
`
`
`
`
`INFORMATION DISCLOSURE
`
`
`
`S“‘TE“"E””’”""”°““T
`
`
`
`
`
`
`
`
`(Not for submission under 37 CFR 1.99)
`
`
`
`
`
`
`
`Filing Date
`
`
`First Named Inventor
`
`
`
`
`
`2011-04-14
`
`Giorgio Calderari
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`41
`
`
`Adis R&D Profile, Palonosetron R8 25259, R8 25259 197, extracted from Drugs in R&D, October 1999, vol.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2, no. 4, pp. 251-52.
`
`
`
`
`
`
`42
`
`
`
`Piraccini, Gaia et al., An Interesting 5-HT3 Receptor Antagonist Antiemetic for Patients Undergoing
`
`
`
`
`
`
`
`
`
`
`
`
`
`Chemotherapy-Based Conditioning Regimens?, extracted from Blood, Nov. 16, 2001, vol. 98, no. 11, part 2,
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`p. 350b, abstract no. 5169.
`
`
`
`
`
`
`I Stacher,Georg,PalonosetronHelsinn,extractedfromCurrentOpinioninInvestigationalDrugs,October
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2002, vol. 3, no.10, pp. 1502-7.
`
`
`
`
`
`
`
`
`
`Navari, Rudolph M., Pathogenesis—Based Treatment of Chemotherapy—Induced Nausea and Vomiting— Two
`
`
`
`
`
`
`
`
`
`New Agents, extracted from Journal a/Supportive Oncology, 2003, vol. 1(2), pp. 89-103.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Chaitow, 1990, 3 pages
`
`
`
`
`
`
`I I
`
`
`
`
`
`If you wish to add additional non-patent literature document citation information please click the Add button
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`EXAMINER SIGNATURE
`
`
`
`
`
`
`
`Examiner Signature
`
`
`
`
`
`
`/SW36 Gembeh/l(0?/'06/I201?‘
`
`
`
`*EXAM|NER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`citation if not in conformance and not considered.
`Include copy of this form with next communication to applicant.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Date Considered
`
`
`
`2 Enter office that issued the document, by the two—letter code (WIPO
`Q_':.g’_ or MPEP 901.04.
`1 See Kind Codes of USPTO Patent Documents at x-*.-'‘»
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`of the year of the reign of the Emperor must precede the serial number of the patent document.
`Standard ST.3).
`3 For Japanese patent documents, t
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.
`5 Applicant is to place a check mark here i
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`English language translation is attached.
`
`
`
`
`
`
`EFSWeb2.1.17
`
`
`
`
`
`
`
`
`
`
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE UNEE) THROUGH.
`
`
`
`/SG./’
`
`
`
`Page 8 of 8